Dr. Reddy's Forms Technology and Manufacturing Pact in Russia - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Dr. Reddy's Forms Technology and Manufacturing Pact in Russia

ePT--the Electronic Newsletter of Pharmaceutical Technology

Dr. Reddy’s Laboratories (Hyderabad, Andhra Pradesh, India) has entered into a technology transfer, manufacturing, and marketing agreement with R-Pharm (Moscow), a Russian pharmaceutical company. The agreement is based on a profit-sharing model and will entail licensing of manufacturing know-how of products by Dr. Reddy’s, local manufacturing of products in Russia, codevelopment of high-technology products, and knowledge sharing between the two companies.

R-Pharm was founded in 2001 and is involved in research and development (R&D), manufacturing of active ingredients and finished drug products, promotion, and distribution of pharmaceuticals used in hospitals and specialty care. It employs approximately 400 people and has 15 affiliates in the Russian Federation.

“We are excited about the collaboration as it helps us to deepen our engagement with Russia, one of our key markets,” said Satish Reddy, managing director and COO of Dr. Reddy’s in a Dec. 21, 2010, press release. “The agreement allows us to bring innovative medicines to the Russian people with active collaboration of a local pharmaceutical company, R-Pharm. It will also allow Dr. Reddy’s to import and market R-Pharm products in India according to agreed terms. The collaboration demonstrates our commitment to play a leading role in supporting the Russian government’s policy of Pharma 2020.”

Pharma 2020 is a plan by the Russian government to develop R&D and manufacturing of drugs by Russia’s domestic pharmaceutical sector. The plan seeks to elevate the market share of domestically produced generic and innovator drugs through increased investments in technology as well as R&D.

Dr. Reddy’s signed the agreement with R-Pharm at the India–Russia Forum on Trade and Investment in New Delhi on Dec. 20, 2010. The forum coincided with the visit of Russian President Dmitriy Medvedev to India.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here